Earlier Lifeline for Rural Hospitals Faces Test Under ‘Big Beautiful’ Law

• by Sarah Jane Tribble, Tony Leys

• August 3, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

• by Kathryn Wighton

• June 26, 2026

• 3 min

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

• by Kathryn Wighton

• May 29, 2026

• 5 min

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min